Shaji K. Kumar, MD, U.S.
Consultant in the Division of Hematology and the Mark and Judy Mullins Professor of Hematological Malignancies at the Mayo Clinic in Rochester, Minnesota.聽
Risk stratification in smoldering myeloma
Risk stratification in smoldering multiple myeloma (SMM) is evolving beyond baseline clinical parameters鈥攕uch as M-protein levels, bone marrow plasma cell infiltration, and free light chain ratios鈥攖o include dynamic biomarkers that reflect disease progression over time. This lecture will highlight the widely adopted 鈥2/20/20鈥 model, which identifies high-risk SMM based on M-protein >2鈥痝/dL, bone marrow plasma cells >20%, and a free light chain ratio >20. These advancements in risk assessment are critical for identifying patients at highest risk of progression to symptomatic myeloma, enabling timely and potentially disease-modifying early intervention.
2025-11-19
